A French stockholder sued a California biotechnology company and its board over alleged violations of the Securities Exchange Act of 1934.
Canan Celebi sued IGM Biosciences, Inc. and its board of directors in relation to the proposed acquisition of IGM by Concentra Biosciences, LLC. The complaint alleges violations of Sections 14(e), 14(d), and 20(a) of the SEC related to materially misleading statements or omissions in the recommendation statement. It was filed in the United States District Court for the Northern District of California.
Plaintiff alleges the recommendation statement filed on July 16, 2025 omits material information regarding the sales process, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.